A Pegylated Flavin Adenine Dinucleotide PEG Complex to Boost Immunogenic and Therapeutic Effects in a Liver Cancer Model.
Journal
Nanotheranostics
ISSN: 2206-7418
Titre abrégé: Nanotheranostics
Pays: Australia
ID NLM: 101698994
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
02
2021
accepted:
03
04
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
22
5
2021
Statut:
epublish
Résumé
Flavin adenine dinucleotide (FAD) is engaged in several metabolic diseases. Its main role is being a cofactor essential for the activity of many flavoproteins, which play a crucial role in electron transport pathways in living systems. The aim of this study was to apply a pegylated flavins formulation named FAD-PEG diacide complex as theranostic pathway in cancer therapy. For this purpose, a mouse liver cancer model induced by Hepa1-6 cells was used to evaluate the therapeutic efficacy of FAD (named NP1) and FAD-PEG diacide complex (named NP2). The cytokines were applied to screen the serum inflammatory factors, to establish the blood cell content of different groups of nude mice. The highlights follows that FAD formulations (NP1; NP2) significantly suppressed the tumor growth and reduced the tumor index without effects on the body weight of mice. Furthermore, NP2 significantly reduced the serum levels of cytokines IL-6, TNF-α and IL-12 (P70). The reported results provide the proof-of-concept for the synthesis of a smart adjuvant for liver cancer therapy and support their further development in the field of nanomedicine.
Identifiants
pubmed: 33912380
doi: 10.7150/ntno.59290
pii: ntnov05p0405
pmc: PMC8077970
doi:
Substances chimiques
Antioxidants
0
Cytokines
0
Flavin-Adenine Dinucleotide
146-14-5
Polyethylene Glycols
3WJQ0SDW1A
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
405-416Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Int J Biol Macromol. 2019 Oct 1;138:986-995
pubmed: 31351152
Semin Cell Dev Biol. 2012 Jun;23(4):370-80
pubmed: 22306135
J Biol Chem. 2013 Oct 4;288(40):29069-80
pubmed: 23946482
Acta Crystallogr D Struct Biol. 2019 Sep 1;75(Pt 9):841-851
pubmed: 31478907
Exp Hematol. 1996 Oct;24(12):1363-8
pubmed: 8913281
Eur J Biochem. 1997 Nov 1;249(3):777-85
pubmed: 9395326
Anal Chem. 2014 Oct 21;86(20):10223-30
pubmed: 25222439
Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):1-15
pubmed: 19947890
Cell Mol Life Sci. 2009 Mar;66(5):788-99
pubmed: 18979208
Int J Nanomedicine. 2020 Mar 03;15:1437-1456
pubmed: 32184597
Commun Biol. 2019 Nov 14;2:414
pubmed: 31754644
Biochem Pharmacol. 2003 Oct 15;66(8):1499-503
pubmed: 14555227
Sci Rep. 2019 Feb 28;9(1):3044
pubmed: 30816163
ACS Appl Mater Interfaces. 2016 Aug 10;8(31):19946-57
pubmed: 27424920
Expert Rev Gastroenterol Hepatol. 2008 Dec;2(6):791-802
pubmed: 19090739
Blood. 1986 Feb;67(2):331-3
pubmed: 3942828
Ther Clin Risk Manag. 2006 Jun;2(2):159-68
pubmed: 18360589
Behav Brain Res. 2017 Jan 1;316:215-224
pubmed: 27599618
Molecules. 2008 Aug 05;13(8):1551-69
pubmed: 18794772
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
J Natl Cancer Inst Monogr. 2001;(29):26-30
pubmed: 11694562
ACS Catal. 2018 Dec 7;8(12):10964-10976
pubmed: 31105987
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Hematol Oncol Clin North Am. 2016 Apr;30(2):373-93
pubmed: 27040960
Biochem Pharmacol. 1990 Aug 1;40(3):559-64
pubmed: 2166517
Cytokine. 2013 Jan;61(1):46-9
pubmed: 23107827
Pharmacol Res. 2011 Oct;64(4):410-9
pubmed: 21723392
Klin Wochenschr. 1970 Sep 1;48(17):1071-2
pubmed: 5523465
Drug Metab Lett. 2016;10(2):83-90
pubmed: 26902079
Cancers (Basel). 2010 Sep 17;2(3):1717-30
pubmed: 24281184
Free Radic Biol Med. 2006 Apr 15;40(8):1293-302
pubmed: 16631519
J Surg Res. 1999 Aug;85(2):251-8
pubmed: 10423326
Curr Drug Metab. 2007 Dec;8(8):822-9
pubmed: 18220563
Front Pharmacol. 2018 Nov 13;9:1300
pubmed: 30483135
Biochem Biophys Res Commun. 2015 Sep 25;465(3):443-9
pubmed: 26277395
Protein Sci. 2001 Sep;10(9):1712-28
pubmed: 11514662
Nat Commun. 2019 Oct 8;10(1):4571
pubmed: 31594944
Br J Pharmacol. 2009 Oct;158(3):679-92
pubmed: 19775280
J Org Chem. 2007 Aug 17;72(17):6329-42
pubmed: 17580897
J Food Sci Technol. 2011 Aug;48(4):412-22
pubmed: 23572765
Biomed Pharmacother. 2020 Aug;128:110318
pubmed: 32502840
Oncotarget. 2015 Dec 22;6(41):43679-97
pubmed: 26544897
Scientifica (Cairo). 2016;2016:9828672
pubmed: 27051561
Biochim Biophys Acta. 2014 Nov;1843(11):2563-2582
pubmed: 24892271
Biomed J. 2015 Mar-Apr;38(2):111-6
pubmed: 25163503
FEBS J. 2009 Jan;276(1):219-31
pubmed: 19049514
Br J Cancer. 2013 Oct 1;109(7):1904-7
pubmed: 24008659
Front Immunol. 2019 Mar 06;10:360
pubmed: 30894857
Mediators Inflamm. 2013;2013:480739
pubmed: 23997430